{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:12:44Z","timestamp":1759335164436,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.urolonc.2025.06.018","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T19:41:10Z","timestamp":1754509270000},"page":"664.e11-664.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum Markers as predictors for treatment benefit in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Tibor","family":"Szarvas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Jagarlamudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Styrke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4952-445X","authenticated-orcid":false,"given":"Stig","family":"Linder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.06.018_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0002","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0003","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.urolonc.2025.06.018_bib0004","article-title":"Chemotherapy for hormone-refractory prostate cancer","author":"Shelley","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.urolonc.2025.06.018_bib0005","first-page":"467","article-title":"EAU guidelines office, Arnhem, The Netherlands","volume":"65","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0006","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N E J Med"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0007","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","article-title":"Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review","volume":"23","author":"Patell","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0008","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.annonc.2021.03.205","article-title":"Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial","volume":"32","author":"Annala","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0009","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0010","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/pros.24710","article-title":"Predicting abiraterone efficacy in advanced prostate cancer: insights from marker of proliferation Ki67","volume":"84","author":"Zhao","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.euros.2024.10.010","article-title":"Elevated levels of serum thymidine kinase 1 predict poor survival for patients with metastatic prostate cancer","volume":"70","author":"Murtola","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0012","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/MCB.24.2.514-526.2004","article-title":"Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex\/cyclosome-CDH1-mediated pathway","volume":"24","author":"Ke","year":"2004","journal-title":"Molecul Cell Biol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0013","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/bmm-2018-0157","article-title":"Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker","volume":"12","author":"Jagarlamudi","year":"2018","journal-title":"Biomark Med"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0014","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/pros.23791","article-title":"The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions","volume":"79","author":"Jagarlamudi","year":"2019","journal-title":"Prostate."},{"key":"10.1016\/j.urolonc.2025.06.018_bib0015","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jcb.10173","article-title":"Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis","volume":"85","author":"Sheard","year":"2002","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0016","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/0008-5472.CAN-03-2455","article-title":"Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18","volume":"64","author":"Kramer","year":"2004","journal-title":"Can Res"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000030148","article-title":"The versatility of cytokeratins as tumor markers","volume":"22","author":"Stigbrand","year":"2001","journal-title":"Tumour Biol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0018","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000107582","article-title":"Cytokeratin markers come of age","volume":"28","author":"Linder","year":"2007","journal-title":"Tumour Biol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.hoc.2018.12.005","article-title":"Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy","volume":"33","author":"Rizk","year":"2019","journal-title":"Hematol\/Oncol Clin North Am"},{"year":"2024","series-title":"Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers","author":"Olah","key":"10.1016\/j.urolonc.2025.06.018_bib0020"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0021","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3109\/09553002.2014.892229","article-title":"Cancer biomarker discovery: current status and future perspectives","volume":"90","author":"Mabert","year":"2014","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0022","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3390\/cancers16132448","article-title":"Integrating Omics data and AI for cancer diagnosis and prognosis","volume":"16","author":"Ozaki","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0023","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1080\/0284186X.2023.2254480","article-title":"Ki67 and prostate specific antigen are prognostic in metastatic hormone naive prostate cancer","volume":"62","author":"Spyratou","year":"2023","journal-title":"Acta Oncol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.62347\/EPGV7486","article-title":"Neoadjuvant chemohormonal therapy before radical prostatectomy in high-risk prostate cancer: a mini-review","volume":"12","author":"Fan","year":"2024","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1590\/S1807-59322008000600009","article-title":"Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer","volume":"63","author":"Kato","year":"2008","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.656444","article-title":"Influence of tumor burden on serum prostate-specific antigen in prostate cancer patients undergoing radical prostatectomy","volume":"11","author":"Mandel","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1472-6890-13-24","article-title":"The role and prognostic value of apoptosis in colorectal carcinoma","volume":"13","author":"Alcaide","year":"2013","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0028","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jso.10063","article-title":"Apoptosis and its correlation with proliferative activity in rectal cancer","volume":"79","author":"Kim","year":"2002","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-004-3015-1","article-title":"Apoptosis and proliferation: correlation with p53 in astrocytic tumours","volume":"73","author":"Sarkar","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0030","first-page":"755","article-title":"Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas","volume":"142","author":"Leoncini","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0031","first-page":"5595","article-title":"Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma","volume":"55","author":"Tormanen","year":"1995","journal-title":"Cancer research"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0032","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/bjc.1995.232","article-title":"S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells","volume":"71","author":"Hennequin","year":"1995","journal-title":"Br J Can"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0033","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1158\/1535-7163.MCT-05-0130","article-title":"Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells","volume":"4","author":"Morse","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0034","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(03)14023-8","article-title":"Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer","volume":"362","author":"Chang","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2023.03.031","article-title":"Relationship between baseline prostate-specific antigen on cancer detection and prostate cancer death: long-term follow-up from the European randomized study of screening for prostate cancer","volume":"84","author":"Remmers","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0036","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0022-5347(01)64239-3","article-title":"Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate","volume":"158","author":"Kramer","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.06.032","article-title":"Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker","volume":"214","author":"Linder","year":"2004","journal-title":"Cancer Letters"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0038","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/liv.12322","article-title":"Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts","volume":"34","author":"Thulin","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120147","article-title":"Cytokeratin 18 fragment in liver inflammation and fibrosis: systematic review and meta-analysis","volume":"569","author":"Ye","year":"2025","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13578-020-00493-1","article-title":"Thymidine kinase 1 through the ages: a comprehensive review","volume":"10","author":"Bitter","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1016\/j.urolonc.2025.06.018_bib0041","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:14:39Z","timestamp":1759299279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1078143925002509"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.06.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Markers as predictors for treatment benefit in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}